(Q37461022)

20 August 2017

1 reference

title

Developments in treatment of esophageal/gastric cancer (English)

1 reference

20 August 2017

Wei Liu

1

1 reference

PubMed ID

19396633

20 August 2017

Xiaodong Zhang

series ordinal

2

1 reference

PubMed ID

19396633

20 August 2017

Weijing Sun

series ordinal

3

1 reference

20 August 2017

1 December 2008

1 reference

Current Treatment Options in Oncology

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

4-6

1 reference

20 August 2017

375-387

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-009-0097-1

20 August 2017

0 references

cites work

Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer

1 reference

12 December 2020

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma

1 reference

12 December 2020

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

12 December 2020

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

12 December 2020

Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus

1 reference

12 December 2020

The changing epidemiology of esophageal cancer

1 reference

12 December 2020

Global cancer statistics, 2002

1 reference

12 December 2020

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

12 December 2020

A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).

1 reference

12 December 2020

Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

1 reference

12 December 2020

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

1 reference

12 December 2020

A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma

1 reference

12 December 2020

Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group

1 reference

12 December 2020

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

1 reference

12 December 2020

Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial

1 reference

12 December 2020

A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer.

1 reference

12 December 2020

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

1 reference

12 December 2020

Cancer statistics, 2008

1 reference

12 December 2020

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

12 December 2020

Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study.

1 reference

12 December 2020

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

1 reference

12 December 2020

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

12 December 2020

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

1 reference

12 December 2020

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

1 reference

12 December 2020

Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity

1 reference

12 December 2020

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

1 reference

12 December 2020

10.1007/S11864-009-0097-1

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19396633